(RTTNews) - The U.S. Food and Drug Administration has extended by three months the target action date of its priority review of the supplemental Biologics License Application or sBLA for Dupixent ...

If approved, Dupixent will be the first biologic medicine available in the U.S. to treat uncontrolled moderate-to-severe atopic dermatitis for these young children Atopic dermatitis is a chronic type ...

Please provide your email address to receive an email when new articles are posted on . If approved, Dupixent would be the first and only targeted medicine to treat bullous pemphigoid in the U.S. The ...

Sanofi and Regeneron’s Dupixent is on fire. A week after scoring the first FDA approval for eosinophilic esophagitis, the drug scored priority review for prurigo nodularis. If it wins the agency's ...

FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade Safety results in all LIBERTY-CUPID Phase 3 trials were generally consistent with ...

TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by three months ...

Q. In a recent article about the challenges of treating eczema (atopic dermatitis), you described a number of over-the-counter treatments as well as modern prescription medicines. In particular, you ...

There are approximately 160,000 patients in the U.S. living with eosinophilic esophagitis who are currently treated, of whom approximately 48,000 have failed multiple treatments The sBLA is supported ...

Please provide your email address to receive an email when new articles are posted on . The FDA has accepted for review the supplemental biologics license application for Dupixent for the treatment of ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion, and nasal polyps in patients aged 6 years ...

FDA accepts for priority review Dupixent ® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis *If approved, Dupixent would be the first biologic medicine available ...